PHKB

PHKB encodes the ubiquitously expressed beta subunit of phosphorylase kinase, the multimeric enzyme that activates glycogen phosphorylase to initiate glycogenolysis (PMID:9215682, PMID:36077341). The gene maps to chromosome 16q12-q13, distinguishing it from the X-linked alpha subunit, and is expressed from a 33-exon gene with alternatively spliced isoforms (mutually exclusive exons 26/27 and a facultative exon 2 encoding an alternative N-terminus) (PMID:2757032, PMID:8681948). Beyond its structural role in the holoenzyme, the beta subunit contributes to substrate isoform recognition: an Ala117Pro substitution selectively impairs phosphorylase kinase activity toward the liver phosphorylase isoform while leaving muscle phosphorylase activity intact (PMID:9402963). Phkb-knockout mice exhibit hepatomegaly, reduced fasting blood glucose, and only partial liver glycogen phosphorylase (PYGL) activity, establishing that the beta subunit is required for full activation of the liver phosphorylase isoform during glycogenolysis, with compensatory upregulation of gluconeogenesis and lipid metabolism (PMID:36077341). PHKB also physically engages the C-terminal region of KIAA1199, a interaction linked to glycogen breakdown and cancer cell survival (PMID:25051373). Loss-of-function mutations (nonsense, frameshift, splice-site, and large deletions) cause autosomal recessive glycogen storage disease affecting liver and muscle (GSD-IX-beta) (PMID:9215682, PMID:9326319).

1. 1989 High

   Establishing that the beta subunit is encoded by an autosomal gene distinct from the X-linked alpha subunit defined the genetic architecture underlying tissue-specific and inheritance-pattern differences in phosphorylase kinase deficiency.

   Evidence Southern blot of rodent x human somatic cell hybrid panels and in situ chromosomal hybridization localizing PHKB to 16q12-q13

   PMID:2757032

   Open questions at the time

   • Chromosomal assignment alone does not define gene structure or protein function
   • Does not address how the subunit assembles into the holoenzyme
2. 1996 High

   Determining the full PHKB gene structure and alternative splicing pattern provided the molecular framework needed to interpret mutations and isoform diversity.

   Evidence cDNA and genomic sequencing, library screening, and exon-intron boundary analysis defining 33 exons, mutually exclusive exons 26/27, and facultative exon 2

   PMID:8681948

   Open questions at the time

   • Functional consequences of the spliced isoforms not established
   • No structural model of the subunit within the holoenzyme
3. 1997 High

   Identifying loss-of-function mutations across liver and muscle confirmed that PHKB encodes the ubiquitous beta subunit required for phosphorylase kinase activity and established it as the cause of an autosomal glycogen storage disease.

   Evidence RT-PCR and genomic sequencing of patients revealing nonsense, frameshift, splice-site, and deletion mutations across independent families, including compound heterozygous W609X and a splice-acceptor deletion

   PMID:9215682 PMID:9326319

   Open questions at the time

   • Why hepatic involvement is severe while erythrocyte/muscle involvement is mild is not mechanistically resolved
   • Genotype-phenotype relationships across mutation classes incompletely mapped
4. 1997 Medium

   A point mutation that selectively impaired activity toward liver but not muscle phosphorylase showed that the beta subunit itself contributes to substrate isoform recognition, not merely structural assembly.

   Evidence RT-PCR mutation analysis plus enzyme activity assays using liver versus muscle phosphorylase isoforms as substrates in patient leukocytes (Ala117Pro)

   PMID:9402963

   Open questions at the time

   • Single patient/single lab observation
   • Structural basis of the Ala117 region's isoform discrimination not defined
5. 2014 Medium

   Discovery of a physical PHKB-KIAA1199 interaction extended the beta subunit's relevance beyond classical glycogenolysis to a glycogen-breakdown axis supporting cancer cell survival.

   Evidence Pull-down assay with KIAA1199-MBP fusion and retroviral overexpression in cancer cell lines with glycogen breakdown and survival readouts

   PMID:25051373

   Open questions at the time

   • Single lab without reciprocal validation in primary tissue
   • Whether the interaction modulates holoenzyme activity directly is unknown
6. 2022 High

   A knockout mouse demonstrated in vivo that the beta subunit is required for full activation of liver phosphorylase during glycogenolysis, with metabolic compensation revealing systemic consequences of beta-subunit loss.

   Evidence Phkb-/- mice analyzed by fasting glucose/ketone measurement, glycogen phosphorylase activity assay, pyruvate tolerance test, expression analysis, and liver histology

   PMID:36077341

   Open questions at the time

   • Residual partial phosphorylase activity in the absence of beta subunit is unexplained
   • Mechanism of compensatory gluconeogenesis/lipid upregulation not dissected

• The structural basis for how the beta subunit confers substrate isoform recognition and regulates holoenzyme activation remains unresolved.
• No structural model of PHKB within the (alpha-beta-gamma-delta)4 holoenzyme
• Functional roles of the alternatively spliced isoforms uncharacterized
• Physiological significance of the KIAA1199 interaction in normal tissue not established